Clinical Trial Update: A Study of ABP 215 Versus Bevacizumab in Chinese Subjects With Advanced Non-Squamous Non-Small Cell Lung Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial comparing ABP 215 to bevacizumab in Chinese patients with advanced non-squamous non-small cell lung cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• ABP 215
• Bevacizumab (bevacizumab)

Snippet

Sponsor: Amgen | Conditions: Metastatic Non-small Cell Lung Cancer (NSCLC), Non-squamous NSCLC | Phase 3 | Status: WITHDRAWN